FDx Advisors Inc. Sells 668 Shares of Alexion Pharmaceuticals, Inc. (ALXN)
FDx Advisors Inc. trimmed its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 5.9% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 10,614 shares of the biopharmaceutical company’s stock after selling 668 shares during the quarter. FDx Advisors Inc.’s holdings in Alexion Pharmaceuticals were worth $1,489,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Commerzbank Aktiengesellschaft FI increased its stake in shares of Alexion Pharmaceuticals by 151.5% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock worth $16,145,000 after buying an additional 79,943 shares during the period. HPM Partners LLC increased its stake in shares of Alexion Pharmaceuticals by 267.2% in the second quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company’s stock worth $656,000 after buying an additional 4,861 shares during the period. Principal Financial Group Inc. increased its stake in shares of Alexion Pharmaceuticals by 1.2% in the second quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock worth $40,823,000 after buying an additional 4,115 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Alexion Pharmaceuticals by 4,509.0% in the third quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock worth $124,037,000 after buying an additional 864,967 shares during the period. Finally, IFC Holdings Incorporated FL purchased a new position in shares of Alexion Pharmaceuticals in the third quarter worth $861,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.
In related news, EVP Julie O’neill sold 11,160 shares of the company’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $140.00, for a total value of $1,562,400.00. Following the transaction, the executive vice president now owns 26,704 shares in the company, valued at approximately $3,738,560. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the transaction, the director now owns 5,480 shares in the company, valued at approximately $799,038.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,490 shares of company stock worth $2,337,251. 4.35% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “FDx Advisors Inc. Sells 668 Shares of Alexion Pharmaceuticals, Inc. (ALXN)” was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/fdx-advisors-inc-sells-668-shares-of-alexion-pharmaceuticals-inc-alxn/1702283.html.
Alexion Pharmaceuticals, Inc. (ALXN) opened at $113.45 on Tuesday. The stock has a market cap of $25,350.00, a PE ratio of 23.55, a P/E/G ratio of 1.25 and a beta of 1.22. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million for the quarter, compared to analysts’ expectations of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. Alexion Pharmaceuticals’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.23 EPS. analysts expect that Alexion Pharmaceuticals, Inc. will post 4.81 earnings per share for the current year.
Several research analysts recently commented on ALXN shares. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, October 23rd. Royal Bank Of Canada lifted their target price on shares of Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. Stifel Nicolaus decreased their target price on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research note on Tuesday, October 24th. Finally, Leerink Swann lifted their target price on shares of Alexion Pharmaceuticals from $136.00 to $170.00 and gave the stock an “outperform” rating in a research note on Friday, July 28th. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $154.01.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.